Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
Morning wrap: Strong Wall Street, weak Europe and Asia 🚩 NFP to test equity strength
Daily Summary: Wall Street Recovers as Micron Shines and Oil Prices Rise Again
Stock of the Week: Micron. The Memory Cycle in the Age of Artificial Intelligence
US Open: Micron restores faith in the never-ending AI boom